{"id":88576,"date":"2019-03-11T19:42:35","date_gmt":"2019-03-12T02:42:35","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/03\/snipr-raises-50m-to-use-crispr-to-modulate-the-microbiome"},"modified":"2019-03-11T19:42:35","modified_gmt":"2019-03-12T02:42:35","slug":"snipr-raises-50m-to-use-crispr-to-modulate-the-microbiome","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/03\/snipr-raises-50m-to-use-crispr-to-modulate-the-microbiome","title":{"rendered":"Snipr raises $50M to use CRISPR to modulate the microbiome"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/snipr-raises-50m-to-use-crispr-to-modulate-the-microbiome.jpg\"><\/a><\/p>\n<p>Snipr Biome has <a href=\"https:\/\/static1.squarespace.com\/static\/5bacc67990f9041ab0d5b0c1\/t\/5c84f78de2c48349ec78bbaf\/1552217998700\/190311_SNIPR_PRESS_RELEASE_FINAL.pdf\">raised<\/a> (PDF) $50 million (\u20ac43 million, DKK320 million) to take CRISPR-based microbiome drugs into clinical trials. The Danish biotech is using CRISPR\/Cas to selectively target and kill bacteria with specific DNA sequences.<\/p>\n<p>Christian Gr\u00f8ndahl, the CEO of Snipr, began working with his co-founders on the use of gene editing to modify or kill bacteria shortly after he left Kymab in 2015. The work led to a series of patents on altering microbiota, for reasons including immune modulation, and a \u20ac2.6 million investment from Lundbeckfonden Emerge to support research into potential applications for the technology.<\/p>\n<p>Now, Lundbeckfonden has joined with Dutch VC shop LSP to lead a $50 million series A round. The jump in funding follows a period in which Snipr has begun to validate its technology and refine its R&amp;D strategy.<\/p>\n<p><!-- Link: <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/snipr-raises-50m-to-use-crispr-to-modulate-microbiome\">https:\/\/www.fiercebiotech.com\/biotech\/snipr-raises-50m-to-us...microbiome<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Snipr Biome has raised (PDF) $50 million (\u20ac43 million, DKK320 million) to take CRISPR-based microbiome drugs into clinical trials. The Danish biotech is using CRISPR\/Cas to selectively target and kill bacteria with specific DNA sequences. Christian Gr\u00f8ndahl, the CEO of Snipr, began working with his co-founders on the use of gene editing to modify or [\u2026]<\/p>\n","protected":false},"author":396,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11],"tags":[],"class_list":["post-88576","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/88576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/396"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=88576"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/88576\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=88576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=88576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=88576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}